scholarly journals Cost variation analysis of ACE inhibitors in India

2017 ◽  
Vol 6 (6) ◽  
pp. 1522
Author(s):  
Prashant Wadagbalkar ◽  
Poonam Patel ◽  
Swati V. Raipurkar
Keyword(s):  
Ace Inhibitors ◽  
Antihypertensive Drugs ◽  
Patient Adherence ◽  
Antihypertensive Agents ◽  
Cost Ratio ◽  
Medical Specialties ◽  
Single Drug ◽  
Cost Variation ◽  
The Difference ◽  
The Cost

Background: Cardiovascular diseases are the most prevalent cause of death and disability in developed and developing countries. There is a wide variation in the prices of antihypertensive drugs marketed in India. Thus, a study was planned to find out variation in cost in the ACE Inhibitors available in India either as a single drug or in combination and to evaluate the difference in cost of various brands of the same ACE Inhibitors and ARBs by calculating percentage variation in cost in Indian rupees.Methods: Minimum and maximum costs in rupees (INR) of antihypertensive agents manufactured by different companies, in the same strength and dosage forms were obtained from “current index of medical specialties” January April 2016 and Drug Today October-December 2016. The cost ratio and percentage cost variation were calculated for each generic antihypertensive agent (ACE Inhibitors and ARBs).Results: This study shows that there is a wide variation in the prices of different brands of same ACE Inhibitors and ARBs in Indian market.Highest cost variation 400% is for Lisinopril (2.5mg), followed by Enalapril (10mg) 394.16%, Telmisartan (20mg) 322.22%.Conclusions: There is a wide difference in the cost of different brands of ACE Inhibitors and ARBs available in India. They have important role in management of hypertension particularly if associated with other morbidities like diabetes. The clinicians prescribing these drugs should be aware of these variations in cost so as to reduce the cost of drug therapy and increase the patient adherence to the therapy.

scholarly journals Cost variation analysis of antihypertensive drugs acting through renin angiotensin aldosterone axis modulation

2017 ◽  
Vol 6 (5) ◽  
pp. 1085
Author(s):  
Manju K. Nair ◽  
Neha M. S.
Keyword(s):  
Dosage Form ◽  
Antihypertensive Drugs ◽  
Cost Effective ◽  
Cost Ratio ◽  
Microsoft Excel ◽  
Medical Specialties ◽  
Renin Angiotensin ◽  
Cost Variation ◽  
Rational Drug ◽  
The Cost

Background: Several brands of antihypertensive drugs are available in the Indian market with huge price variations. This study was undertaken to find out the percentage cost variation and cost ratio of antihypertensive drugs acting through renin angiotensin aldosterone axis modulation.Methods: Costs of different brands of renin angiotensin aldosterone axis modulatory drugs with antihypertensive action for the same dosage form and strength were found out using current index of medical specialties-134, July-October 2016. The maximum and minimum price of different brands of each drug was noted. Data was entered in Microsoft excel 2010. Percentage cost variation and cost ratio was calculated for each drug.Results: 16 antihypertensive drugs were analysed. Most of them were tablets. Ramipril and Valsartan were available as capsules also. Among tablets, percentage cost variation was highest for Atenolol 12.5 mg (683.93%) and least for Bisoprolol 2.5 mg (3.6538%). Valsartan capsules (160 mg) had no difference in the costs between the available 2 brands. Cost ratio ranged from 1.04 to 7.84 among the tablet form of drugs.Conclusions: There is a huge difference in the cost of antihypertensive drugs manufactured by different companies in the same strength and dosage form. To promote rational drug use and cost effective therapy, it is essential to create an awareness among clinicians regarding the availability of multiple brands for these drugs and the discrepancies in their costs.

scholarly journals Cost analysis of various topical eye preparations currently available in Indian market

2019 ◽  
Vol 8 (8) ◽  
pp. 1754
Author(s):  
Shweta Agrawal ◽  
Neelesh Arya ◽  
Mehul Agrawal
Keyword(s):  
Cost Ratio ◽  
Eye Drops ◽  
Drug Formulations ◽  
Medical Specialties ◽  
Cost Variation ◽  
Long Run ◽  
The Common ◽  
Cost Of Drugs ◽  
The Cost ◽  
Indian Pharmaceutical Industry

Background: topical eye preparations are very commonly used in India for different eye diseases hence their prices should not be much different in Indian pharmaceutical industry. The common man therefore has to shell out more money with medicine prices spinning out of his reach. Aim of this study was to compare the cost of drugs of the different brand of topical ophthalmic drugs.Methods: cost of various topical eye preparations was compared using “Current Index of Medical Specialties” (CIMS) January-April 2019 and cost variation was recorded. Drugs were categorized into anti-infective and antiseptics, topical corticosteroids, mydriatics, anti-glaucoma drugs, anti-inflammatory and lubricants.Results: That of the 26 drug formulations studied, the percentage cost variation of 10 drug formulations was more than 100%, out of which one formulation of moxifloxacin had more than 1000% variation. Cost ratio of 10 drug formulations were more than two. Moxifloxacin 0.5% eye drops had maximum percentage cost variation of 5610.66% and cost ratio of 57.11, followed by ofloxacin 0.30% eye drops (310.92%, 4.11), timolol 0.50% eye drops (263.64%, 3.64), ciprofloxacin 0.30% eye drops (142.42%, 2.42), tobramycin 0.30% eye drops (120.14%, 2.20).Conclusions: There is a significant variation in the price of various topical eye preparations. As most of the preparations being prescribed on an out-patient basis, which was not covered under most of the insurance program. Out of pocket expenditure adversely affects the drug compliance in the long run. There should be a comprehensive action from policymakers, regulatory authorities, government agencies, doctors, pharmacists, and the general public to solve this issue of cost variation of drugs.

scholarly journals Study of the Variation in Prices of Antidepressant Drugs Available in Nepali Market

2020 ◽  
Vol 5 (2) ◽  
pp. 1006-1010
Author(s):  
Anjan Khadka ◽  
Pradeep Manandhar ◽  
Nagendra Katuwal ◽  
Mahesh Khatri
Keyword(s):  
Tertiary Care Hospital ◽  
Tertiary Care ◽  
Antidepressant Drugs ◽  
Cost Ratio ◽  
Care Hospital ◽  
Cross Sectional ◽  
Medical Specialties ◽  
Cost Variation ◽  
Multiple Drugs ◽  
The Cost

Introduction: Depression often remains unrecognized, misdiagnosed and/or under treated. There are multiple drugs from multiple companies which are available for treatment of depression. The prices of same drug with different brands are variable which questions the afford ability of treatment to the patients and their compliance. Objective The study was conducted to analyze the cost variation of different brands of antidepressant drugs prescribed in a tertiary care hospital of Nepal. Methodology This study design was cross-sectional and method was quantitative method and conducted at department of pharmacology of a tertiary care hospital from September 2018 to January 2019 after getting approval from institutional review committee. The commonly prescribed antidepressant drugs were recorded from prescription records of department of psychiatry and their cost, cost ratio and percentage variation were calculated as per current index of medical specialties and National index of medical specialties. The data were recorded in MS excel and presented as simple descriptive statistics. Result The study included seven commonly prescribed antidepressants obtained from 214 prescription records. The cost of one course of citalopram 40 mg tablet was found to be higher and the cost of one course of imipramine 25 mg tablet was found to be lower. The maximum and minimum cost ratio was 2.46 and 1.08 with fluoxetine 20 mg capsule and dothiepin 50 mg tablet respectively. The maximum and minimum percentage of cost variation was with fluoxetine 20 mg capsule and dothiepin 50 mg tablet. Conclusion Costs of antidepressants had wider variations depending on the manufacturers and availability of different dose and brands.

scholarly journals Cost variation analysis of commonly prescribed anti-diabetic drugs available in Indian market: a pharmaco-economic study

2021 ◽  
Vol 11 (1) ◽  
pp. 47
Author(s):  
Kajal S. Gupta ◽  
Milind L. Pardeshi ◽  
Rajesh S. Hiray
Keyword(s):  
Minimum Cost ◽  
Rapid Expansion ◽  
Fixed Dose ◽  
Cost Ratio ◽  
Pharmaceutical Pricing ◽  
Price Variation ◽  
Medical Specialties ◽  
Cost Variation ◽  
The Government ◽  
The Cost

Background: Diabetes mellitus (DM) is a chronic metabolic disorder requiring lifelong treatment. Due to rapid expansion of urbanization, unhealthy diet habits and sedentary lifestyle, the incidence of DM is increasing. The chronic nature of DM causes significant personal suffering and economic difficulty to families. The was aimed at investigating the cost difference in various brands of the same oral anti-diabetic drug.Methods: The minimum and the maximum cost in rupees (INR) of a particular anti-diabetic drug manufactured by various pharmaceutical companies were obtained from current index of medical specialties (CIMS) website, Indian drug review (IDR) 2021 issue and National pharmaceutical pricing authority-pharma sahi daam. The cost ratio and percentage cost variation were noted for each brand.Results: Amongst single drug therapy, metformin 500 mg sustained release showed highest price variation (3668%). Minimum cost variation was found with glipizide 2.5 mg (65%). Amongst the fixed dose combinations, highest cost variation was seen with glimepiride 2 mg+metformin 1000 mg (2703%) while minimum cost variation was found with repaglinide 1 mg+voglibose 0.3 mg (29%).Conclusions: A noticeable cost variation was found in different brands of the same anti-diabetic drug. Prescribing a more expensive brand when a cheaper one is available can burden the patient financially and thus reduce patient compliance. In addition, the Government should also include more anti-diabetic drugs under the price control policy to ensure that affordable and efficacious medicines are available to all.Background:  Diabetes mellitus (DM) is a chronic metabolic disorder requiring lifelong treatment. Due to rapid expansion of urbanization, unhealthy diet habits and sedentary life style, the incidence of DM is increasing .The chronic nature of DM causes significant personal suffering and economic difficulty to families. The present study aims at investigating the cost difference in various brands of the same oral anti-diabetic drug.Methods: The minimum and the maximum cost in rupees (INR) of a particular anti-diabetic drug manufactured by various brands were obtained from Current Index of Medical Specialties (CIMS) website, Indian Drug Review (IDR) 2021 issue and National Pharmaceutical Pricing Authority – Pharma sahi daam. The cost ratio and percentage cost variation were noted for each brand.Results: Amongst single drug therapy, Metformin 500mg Sustained Release showed highest price variation (3668%). Minimum cost variation was found with Glipizide 2.5mg (65%).Amongst the fixed dose combinations, highest cost variation was seen with Glimepiride 2mg + Metformin 1000mg (2703%) while minimum cost variation was found with Repaglinide 1mg + Voglibose 0.3mg (29%). Conclusions: A noticeable cost variation was found in different brands of the same anti-diabetic drug. Prescribing a more expensive brand when a cheaper one is available can burden the patient financially and thus reduce patient compliance. In addition, the Government should also include more anti-diabetic drugs under the price control policy to ensure that affordable and efficacious medicines are available to all. Keywords: Anti-diabetic agents, Cost variation, Pharmaco-economics, Adherence, Brands   Background:  Diabetes mellitus (DM) is a chronic metabolic disorder requiring lifelong treatment. Due to rapid expansion of urbanization, unhealthy diet habits and sedentary life style, the incidence of DM is increasing .The chronic nature of DM causes significant personal suffering and economic difficulty to families. The present study aims at investigating the cost difference in various brands of the same oral anti-diabetic drug.Methods: The minimum and the maximum cost in rupees (INR) of a particular anti-diabetic drug manufactured by various brands were obtained from Current Index of Medical Specialties (CIMS) website, Indian Drug Review (IDR) 2021 issue and National Pharmaceutical Pricing Authority – Pharma sahi daam. The cost ratio and percentage cost variation were noted for each brand.Results: Amongst single drug therapy, Metformin 500mg Sustained Release showed highest price variation (3668%). Minimum cost variation was found with Glipizide 2.5mg (65%).Amongst the fixed dose combinations, highest cost variation was seen with Glimepiride 2mg + Metformin 1000mg (2703%) while minimum cost variation was found with Repaglinide 1mg + Voglibose 0.3mg (29%). Conclusions: A noticeable cost variation was found in different brands of the same anti-diabetic drug. Prescribing a more expensive brand when a cheaper one is available can burden the patient financially and thus reduce patient compliance. In addition, the Government should also include more anti-diabetic drugs under the price control policy to ensure that affordable and efficacious medicines are available to all. Keywords: Anti-diabetic agents, Cost variation, Pharmaco-economics, Adherence, Brands   Background:  Diabetes mellitus (DM) is a chronic metabolic disorder requiring lifelong treatment. Due to rapid expansion of urbanization, unhealthy diet habits and sedentary life style, the incidence of DM is increasing .The chronic nature of DM causes significant personal suffering and economic difficulty to families. The present study aims at investigating the cost difference in various brands of the same oral anti-diabetic drug.Methods: The minimum and the maximum cost in rupees (INR) of a particular anti-diabetic drug manufactured by various brands were obtained from Current Index of Medical Specialties (CIMS) website, Indian Drug Review (IDR) 2021 issue and National Pharmaceutical Pricing Authority – Pharma sahi daam. The cost ratio and percentage cost variation were noted for each brand.Results: Amongst single drug therapy, Metformin 500mg Sustained Release showed highest price variation (3668%). Minimum cost variation was found with Glipizide 2.5mg (65%).Amongst the fixed dose combinations, highest cost variation was seen with Glimepiride 2mg + Metformin 1000mg (2703%) while minimum cost variation was found with Repaglinide 1mg + Voglibose 0.3mg (29%). Conclusions: A noticeable cost variation was found in different brands of the same anti-diabetic drug. Prescribing a more expensive brand when a cheaper one is available can burden the patient financially and thus reduce patient compliance. In addition, the Government should also include more anti-diabetic drugs under the price control policy to ensure that affordable and efficacious medicines are available to all. Keywords: Anti-diabetic agents, Cost variation, Pharmaco-economics, Adherence, Brands         

scholarly journals Cost variation analysis of different brands of commonly prescribed antihypertensive drugs, available in Indian market: a pharmacoeconomic study

2018 ◽  
Vol 7 (3) ◽  
pp. 556
Author(s):  
Shakeel Ahmad Mir
Keyword(s):  
Antihypertensive Drugs ◽  
Pharmacoeconomic Study ◽  
Cost Ratio ◽  
Prescription Medications ◽  
Medical Spending ◽  
Cost Variation ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Almost All ◽  
The Cost

Background: Worldwide, Hypertension is estimated to cause 7.5 million deaths, about 12.8% of the total of all deaths. This accounts for 57 million disability adjusted life years (DALYS) or 3.7% of total DALYS. Globally, the overall prevalence of hypertension in adults aged 25 and over was around 40% in 2008.Despite its benefits, treatment of hypertension is costly. Direct medical spending to treat hypertension totalled $42.9 billion in 2010, with almost half ($20.4 billion) in the form of prescription medications. Being, a silent disease, adherence to antihypertensive drugs is poor. One of the important factors of poor adherence to antihypertensives is the cost of the drugs. There is wide cost variation among different brands of the same antihypertensive drug. Clinician’s awareness of cost of therapeutics is poor. The costly brand of same generic drug is proved to be in no way superior to its economically cheaper counterpart.Methods: The minimum and the maximum cost in Rupees (INR) of a particular antihypertensive agent manufactured by various pharmaceutical companies in the same strength were noted. The cost of 10 tablets/capsules was calculated. The cost ratio and percent cost variation were calculated for each brand.Results: The cost variation observed in the present study was as high as 2337.50 % for Hydralazine. Other significantly high cost variations found in the present study were: 1315.25% (Telmisartan+Hydrochlorthiazide), 870.58% (Amlopdipine), 558.34% (Amlodipine+Atenolol), 537.68% (Valsartan), 394.44% (Metoprolol), 344.44% (Enalapril), 316.22% (Propranolol), 300% (Lisinopril), 290.90% (Carvedilol), 289% (Cilnidipine), 271.99% ( Labetolol), 268.04% (Indapamide), 256.31% (Losartan), 255.19% (Irbesartan), 226% (Methyldopa), 223.04% (Frusemide), 209.78% (Nitrendepine), 192.08% (Terazosin), 189.25% (Atenolol), 142.42% (Bisoprolol) and 120.51% (Felodipine).Conclusions: Financial constraints are a reality in almost all aspects of medicine. Doctors must consider drug costs to their patients. Increasing pharmaceutical costs negatively impacts patients. Given the increasing healthcare costs, there is growing interest in rational prescribing, which takes costs of medication into account.

scholarly journals Cost variation analysis study of oral anti-depressant drugs available in India

2017 ◽  
Vol 6 (4) ◽  
pp. 973
Author(s):  
Chaithra K. N. ◽  
Laxminarayana Kamath
Keyword(s):  
Economic Burden ◽  
Patient Adherence ◽  
Antidepressant Drug ◽  
Antidepressant Drugs ◽  
Adherence To Treatment ◽  
Price Variation ◽  
Medical Specialties ◽  
Cost Variation ◽  
Maximum Price ◽  
The Cost

Background: Depression is a disorder of major public health importance, in terms of its prevalence and the suffering, dysfunction, morbidity and economic burden. In India, the overall prevalence of depression is reported to be 15.9%. Antidepressant drugs are available in many different brands and costs of all brands are different. Patients of depression have to take the antidepressant drug for a long duration, so cost of the antidepressant drug influence the patient adherence to treatment and it is one of the important part of rational prescription.Methods: The cost of a particular drug being manufactured by different companies in the same strength and dosage forms was obtained from “Current Index of Medical Specialties” July-October, 2015, and “DrugsUpadate.com”. The cost ratio and percentage cost variation was calculated.Results: The prices of a total of 28 drugs (22 single and 6 combination preparations) available in 64 different formulations were analyzed. In single drug therapy, among Tri cyclic antidepressants (TCAs), Reboxetine (2 mg) showed the maximum price variation of 900%. In SSRIs, Dapoxetine (30 mg) showed the maximum price variation of 2360%. In SNRIs, Venlafaxine (75 mg) showed the maximum price variation of 109%. In Atypical antidepressants, Bupropion (150 mg) showed the maximum price variation of 515.38%. In RIMAs, Moclobemide (150 mg) showed the maximum price variation of 246.15% and in combination therapies, Amitriptyline with Chlordiazepoxide showed the maximum price variation of 129.35%.Conclusions: This study shows a wide variation in the prices of oral Anti-depressant drugs available in India. Psychiatrist/ Physician should consider the cost while prescribing antidepressant drugs. India being developing country most of the people belong to poor socioeconomic status, so prescribing same generic drug with low cost reduces economic burden and improves patient adherence to treatment which results in better outcome.

Arterial Stiffness, Cognitive Dysfunction and Adherence to Antihypertensive Agents. Is there a Link to Hypertensive Patients?

2020 ◽  
Vol 18 (4) ◽  
pp. 410-417 ◽  
Author(s):  
Rigas G. Kalaitzidis ◽  
Thalia Panagiotopoulou ◽  
Dimitrios Stagikas ◽  
Kosmas Pappas ◽  
Olga Balafa ◽  
...  
Keyword(s):  
Cognitive Function ◽  
Arterial Stiffness ◽  
Cognitive Dysfunction ◽  
Antihypertensive Drugs ◽  
Patient Adherence ◽  
Antihypertensive Agents ◽  
Treatment Compliance ◽  
Poor Adherence ◽  
Large Artery ◽  
Adherence To Medication

:The incidence of hypertension (HTN) and its cardiovascular (CV) complications are increasing throughout the world. Blood pressure (BP) control remains unsatisfactory worldwide. Medical inertia and poor adherence to treatment are among the factors that can partially explain, why BP control rate remains low. The introduction of a method for measuring the degree of adherence to a given medication is now a prerequisite. Complex treatment regimes, inadequate tolerance and frequent replacements of pharmaceutical formulations are the most common causes of poor adherence. In contrast, the use of stable combinations of antihypertensive drugs leads to improved patient adherence.:We aim to review the relationships between arterial stiffness, cognitive function and adherence to medication in patients with HTN.:Large artery stiffening can lead to HTN. In turn, arterial stiffness induced by HTN is associated with an increased CV and stroke risk. In addition, HTN can induce disorders of brain microcirculation resulting in cognitive dysfunction. Interestingly, memory cognitive dysfunction leads to a reduced adherence to drug treatment. Compliance with antihypertensive treatment improves BP control and arterial stiffness indices. Early treatment of arterial stiffness is strongly recommended for enhanced cognitive function and increased adherence.

scholarly journals COST ANALYSIS OF DISEASE MODIFYING ANTI RHEUMATIC DRUGS: THE INDIAN SCENARIO

2020 ◽  
pp. 1-2
Author(s):  
Zarrin Ansari ◽  
Sharmada Nerlekar ◽  
Sagar Karia ◽  
Sudhir Pawar
Keyword(s):  
Rheumatoid Arthritis ◽  
Work Capacity ◽  
Biological Agents ◽  
Medical Specialties ◽  
Cost Variation ◽  
Conscious Choice ◽  
Socioeconomic Burden ◽  
Disease Modifying ◽  
The Cost ◽  
Indian Scenario

Background: Rheumatoid arthritis is a chronic, autoimmune and inflammatory disease affecting the joints and cartilages, eventually leading towards deformity and resultant disability. Today’s rheumatologists have an armamentarium of Disease Modifying Anti Rheumatic Drugs (DMARDs) to choose from. The chronicity of the disease, resultant deformities and reduced work capacity adds to the socioeconomic burden of the disease. This study aims to compare the costs of various brands of DMARDs (both biological and non-biological agents), so as the give the readers an idea about the cost range and variation present amongst the available DMARDs. Materials and Methods: Current Index of Medical Specialties (CIMS India) application was accessed in the month of August 2020 to note the cost of various brands of DMARDs. The information was tabulated. The cost difference and percentage cost variation was calculated and compared. Results:The maximum number of brands was available for methotrexate amongst the biological as well as non-biological agents. Least and highest percentage cost variation was observed for 2.5 mg strength of methotrexate and 100 mg of cyclosporine, respectively. In general, biologicals had fewer brands in the market as the cost was considerably higher than the non-biological agents. Conclusion:There is a wide variation amongst the costs of various DMARDs. This has its own advantages. Conscious choice of economical brands can profoundly effect the socioeconomic burden of rheumatoid arthritis management.

scholarly journals ANALISIS PENDAPATAN USAHATANI KAKAO DI DESA SIONTAPINA KECAMATAN LASALIMU SELATAN KABUPATEN BUTON

2018 ◽  
Vol 2 (2) ◽  
pp. 111-122
Author(s):  
Suriadi Suriadi
Keyword(s):  
New Technologies ◽  
Secondary Data ◽  
Simple Random Sampling ◽  
Cost Ratio ◽  
Land Area ◽  
A Value ◽  
Cocoa Production ◽  
Cost Of Production ◽  
The Difference ◽  
The Cost

This research aims to analyze the amount of income earned by farmers from cocoa farming. This research was conducted from May to June 2013 in Siontapina village of Lasalimu Sub-district of Buton Regency. The research sample is determined by sample random techniques (Simple random sampling method) with 30 people. Research data obtained through direct interviews with farmer respondents using a questionnaire. While secondary data is obtained from the village office/administrative and related institutions were analyzed descriptively and quantitatively used to determine the level of income by the formula : N1 = TR- TC, TR = P x Q, TC = TFC + TVC, comparative analysis: Revenue - cost ratio for comparing the difference between the value of production and the cost of production by the formula RC ratio : R/C = Revenue (TR) / Total Cost (TC). The results showed that the income earned by farmers from cocoa farming with land area ranges between 1 to 3 ha of IDR 8,109,000 - 35,437,000/year, with income per capita monthly average IDR 675,750,00 so that Siontapina village had not been considered poor, the average income earned by farmers in cocoa farming with land area- average of 2,05 hectares of IDR 18,426,767/year. Cocoa farming by farmers still does because based on the results of feasibility analysis obtained a value of 5.7. This illustrates that every cost IDR 1.00 incurred by farmers will gain acceptance by IDR 5.7. So, farmers are expected to carry cocoa farming is more responsive and responsive to the presence of new technologies that can increase cocoa production.   Keywords: revenue, cost of production, cocoa.

scholarly journals A study of the cost analysis of various oral antihypertensive drugs available in Indian market

2019 ◽  
Vol 8 (8) ◽  
pp. 1850
Author(s):  
Neelesh Arya ◽  
Shweta Agrawal ◽  
Mehul Agrawal
Keyword(s):  
Public Health ◽  
Effective Treatment ◽  
Antihypertensive Drugs ◽  
Public Health Problem ◽  
Price Variation ◽  
Medical Specialties ◽  
Average Percentage ◽  
Public Health Burden ◽  
Cost Effective Treatment ◽  
The Cost

Background: Hypertension is a serious global public health problem. It accounts for 10% of all deaths in India and is the leading non-communicable disease. Recent studies have shown that the prevalence of hypertension is 25% in urban and 10% in rural people in India. It exerts a substantial public health burden on cardiovascular health status and health care systems in India. Antihypertensive treatment effectively reduces hypertension related morbidity and mortality. The cost of medications has always been a barrier to effective treatment. The increasing prevalence of hypertension requires use of cost effective treatment for the effective management of the disease.Methods: Cost of a particular drug (cost per 10 tablets) in the same strength and dosage forms being manufactured by different companies was obtained from Current Index of Medical Specialties, Jan‑April 2019 and “Indian Drug Review” (IDR) September 2018. Difference between the maximum and minimum cost of the same drug manufactured by different pharmaceutical companies was calculated and percentage cost variation was calculated.Results: The prices of a total of 24 drugs (15 single and 9 combination preparations), available in 59 different formulations were analysed. These 62 formulations are manufactured by different pharmaceutical companies.Conclusions: The average percentage price variation of different brands of the same oral antihypertensive drug manufactured in India is very wide. The appraisal and management of marketing drugs should be directed toward maximizing the benefits of therapy and minimizing negative personal and economic consequences.

Sign in / Sign up

Export Citation Format

Share Document